Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin-Reference-Cited by-同舟云学术

Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin

Published:2022-02-01 Issue:1 Volume:37 Page:2-10
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Hua Li¹,Chen Shaojun¹,Wei Mengzhuan¹,Shen Yongqi²,Long Jianxin³,Lin Zhan⁴,Meng Yiliang⁵,Guo Chengxian⁶,Huang Haixin¹,Tu Xiaoning⁷,Yao Min⁸

Affiliation:

1. Department of Oncology, the Forth Affiliated Hospital of Guangxi Medical University, Liuzhou, China.

2. Department of Oncology, The Liuzhou Railway Affiliated Hospital of Guangxi Medical University, Liuzhou, China.

3. Department of Oncology, Qinzhou Hospital of Traditional Chinese Medicine, Qinzhou, China.

4. Department of Oncology, The Yulin First People's Hospital, Yulin, China.

5. Department of Oncology, The Baishe People's Hospital, Baishe, China.

6. Clinical Pharmacology Center, The Third Xiangya Hospital of Central South University, Changsha, China.

7. Department of Head and Neck Surgery, the Forth Affiliated Hospital of Guangxi Medical University, Liuzhou, China.

8. Department of Radiation Onclogy, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2020.4474

Reference41 articles.

1. Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013

2. Cancer statistics, 2018

3. Update on Nasopharyngeal Carcinoma

4. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial